Mariner
DYN icon

Mariner’s Dyne Therapeutics DYN Stock Holding History

Mariner’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309K Sell
13,904
-2,185
-14% -$40.6K ﹤0.01% 2826
2026
Q1 		$292K Buy
+16,089
New +$277K ﹤0.01% 2908
2025
Q4 		– Sell
-19,541
Closed -$247K – 3609
2025
Q3 		$247K Buy
19,541
+7,588
+63% +$86.5K ﹤0.01% 2984
2025
Q2 		$114K Sell
11,953
-13,699
-53% -$151K ﹤0.01% 3216
2025
Q1 		$268K Buy
25,652
+14,495
+130% +$207K ﹤0.01% 2732
2024
Q4 		$263K Sell
11,157
-1,667
-13% -$49.3K ﹤0.01% 2751
2024
Q3 		$461K Buy
12,824
+1,855
+17% +$73.8K ﹤0.01% 2199
2024
Q2 		$387K Buy
10,969
+1,224
+13% +$35.6K ﹤0.01% 2254
2024
Q1 		$277K Buy
+9,745
New +$220K ﹤0.01% 2509

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mariner's DYN Position: Q2 2026 in Review

Mariner reduced its Dyne Therapeutics (DYN) stake by 14% in Q2 2026, selling an estimated $40.6K and leaving 13,904 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #2826.

Mariner first reported a position in DYN in Q1 2024 and has held it in 9 quarters since. The position peaked at $461K in Q3 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Mariner held 13,904 shares of Dyne Therapeutics worth $309K as of Q2 2026.
  • Mariner sold 2,185 Dyne Therapeutics shares in Q2 2026, an estimated $40.6K.
  • Dyne Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2826 holding.
  • Mariner first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Mariner's Dyne Therapeutics position peaked at $461K in Q3 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.